Home » Stocks » VBLT

Vascular Biogenics Ltd. (VBLT)

Stock Price: $2.23 USD -0.10 (-4.29%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
After-hours: $2.24 +0.01 (0.45%) Jun 18, 6:58 PM
Market Cap 134.44M
Revenue (ttm) 741,000
Net Income (ttm) -25.16M
Shares Out 60.29M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $2.23
Previous Close $2.33
Change ($) -0.10
Change (%) -4.29%
Day's Open 2.31
Day's Range 2.20 - 2.36
Day's Volume 351,920
52-Week Range 1.01 - 3.17

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vascular Biogenics Ltd. ("VBL" or the "Company") (NASDAQ: VBLT).

4 days ago - PRNewsWire

The FDA notified VBL Therapeutics Ltd (NASDAQ: VBLT) that clearance of new VB-111 batches for use in the U.S. is currently pending, as review by the Chemistry, Manufacturing, and Controls (CMC) group is...

5 days ago - Benzinga

TEL AVIV, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced a primary endpoint amendment in the OVAL Phase 3 registration-enabling study of VB-111. The clinical t...

2 weeks ago - GlobeNewsWire

TEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in...

1 month ago - GlobeNewsWire

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and -7.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Conference Call and Webcast at 8:30 a.m. EDT Today

1 month ago - GlobeNewsWire

Vascular Biogenics (NASDAQ:VBLT) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.

1 month ago - Benzinga

TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the closing of its underwritten public offering of 6,90...

2 months ago - GlobeNewsWire

TEL AVIV, Israel, April 09, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the pricing of an underwritten public offering of 5,150...

2 months ago - GlobeNewsWire

TEL AVIV, Israel, April 08, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced that it intends to offer and sell ordinary shares and, ...

2 months ago - GlobeNewsWire

Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gain...

Other stocks mentioned: ACY, BTX, CARA, EEIQ, FHS, PSAC, WEI ...
2 months ago - InvestorPlace

TEL AVIV, Israel, March 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it will host a virtual R&D Day for analysts and investors beginning at 10:00am ET on Tuesday, Ap...

2 months ago - GlobeNewsWire

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -15.38% and 2.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Vascular Biogenics (NASDAQ:VBLT) rose 8.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 6.25% over the past year to ($0.15), whic...

2 months ago - Benzinga

Conference Call and Webcast at 8:30 a . m . EDT Today

2 months ago - GlobeNewsWire

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

TEL AVIV, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the Company will participate in the following upcoming virtual investor conferences:

3 months ago - GlobeNewsWire

Vascular Biogenics Ltd (NASDAQ: VBLT) announced positive results of the pre-specified interim analysis of the Phase 3 OVAL study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovaria...

3 months ago - Benzinga

Vascular Biogenics Ltd (NASDAQ: VBLT) announces results from the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 study of VB-111 in recurrent ovarian c...

3 months ago - Benzinga

TEL AVIV, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company's proprietary ...

4 months ago - GlobeNewsWire

Agreement extends current cash runway to Q1 2023 Agreement extends current cash runway to Q1 2023

5 months ago - GlobeNewsWire

TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the...

5 months ago - GlobeNewsWire

TEL AVIV, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...

6 months ago - GlobeNewsWire

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 28.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Shares of Vascular Biogenics (NASDAQ:VBLT) moved higher by 0.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 14.29% year over year to ($0.12)...

7 months ago - Benzinga

- Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population with ...

7 months ago - GlobeNewsWire

TEL AVIV, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...

7 months ago - GlobeNewsWire

TEL AVIV, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...

7 months ago - GlobeNewsWire

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to becoming ...

8 months ago - GlobeNewsWire

TEL AVIV, Israel, Oct. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent #3328408, which covers VBL’s proprietary inv...

8 months ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-cla...

8 months ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-cla...

8 months ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22n...

9 months ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational a...

9 months ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combinat...

9 months ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (F...

9 months ago - GlobeNewsWire

Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -15.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Shares of Vascular Biogenics (NASDAQ:VBLT) decreased 9% in pre-market trading after the company reported Q2 results.

10 months ago - Benzinga

TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned i...

10 months ago - GlobeNewsWire

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-clas...

10 months ago - GlobeNewsWire

The company's bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer The company's bi-specific antibody candidates significantly prolon...

11 months ago - GlobeNewsWire

TEL AVIV, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced the presentation of the positive outcome of pre-planned interim analysis results from the OVAL Phas...

1 year ago - GlobeNewsWire

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of Vascular Biogenics (NASDAQ:VBLT) were flat in pre-market trading after the company reported Q1 results.

1 year ago - Benzinga

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 6.25% and 89.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Conference Call and Webcast at 8:30am Eastern Time Today Conference Call and Webcast at 8:30am Eastern Time Today

1 year ago - GlobeNewsWire

About VBLT

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinica... [Read more...]

Industry
Biotechnology
IPO Date
Oct 1, 2014
CEO
Dror Harats
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
VBLT
Full Company Profile

Financial Performance

In 2020, VBLT's revenue was $922,000, an increase of 64.06% compared to the previous year's $562,000. Losses were -$24.23 million, 24.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for VBLT stock is "Buy." The 12-month stock price forecast is 5.75, which is an increase of 157.85% from the latest price.

Price Target
$5.75
(157.85% upside)
Analyst Consensus: Buy